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Special Focus on the EXCEL Trial
With evolving stent technology, improvements in percutaneous 
coronary intervention (PCI) techniques and the use of antithrombotic 
medications, the role of PCI in the treatment of left main stem (LMS) 
disease has expanded from being confined to salvage scenarios to 
intermediate- and lower-risk patients. However, the role and benefits of 
coronary artery bypass grafting (CABG) surgery in the treatment of 
multivessel disease and LMS disease have been well established with 
long-term follow-up. In order to assess the role and efficacy of PCI in 
LMS disease compared with CABG, several randomised clinical trials 
have been performed. In this review, some of the earlier and later trials 
will be compared. In recent months, one of them – the Evaluation of 
XIENCE Versus Coronary Artery Bypass Graft Surgery for Effectiveness 
of Left Main Revascularization (EXCEL) trial – has attracted a significant 
amount of scientific and media attention.1 This review will outline the 
methodology of EXCEL, as well as other trials on the management of 
LMS disease and summarise the debates around EXCEL including 
statements from professional societies as well as the impact of these 
trials on real-world practice.
PCI Versus CABG for the Treatment 
of Left Main Stem Disease
Earlier trials demonstrated the efficacy and safety of first-generation 
drug-eluting stents (DES) and later trials compared the second-
generation DES with CABG. The outcome measures used in these trials 
include the occurrence of major adverse cardiac and cerebrovascular 
events (MACCE) at short and medium term, early and late mortality of 
cardiac and all-cause reasons, complete revascularisation at the time 
of primary procedure and rate of repeat revascularisation during 
follow-up. The trials include Synergy Between PCI with Taxus and 
Cardiac Surgery (SYNTAX), Premier of Randomized Comparison of 
Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in 
Patients with Left Main Coronary Artery Disease (PRECOMBAT), Left 
Main Coronary Artery Stenting (LEMANS), Nordic Baltic British Left Main 
Revascularisation (NOBLE) and EXCEL.2–6
Evidence from the SYNTAX trial showed the benefits of CABG in LMS 
with a SYNTAX score of >32.2,3 However, in patients with a SYNTAX 
score of <32, PCI and CABG showed similar results. The SYNTAX trial 
was not powered to address the efficacy of PCI versus CABG and 
therefore further studies like NOBLE and EXCEL were needed. EXCEL 
and NOBLE are non-inferiority randomised trials designed to compare 
and evaluate the efficacy of PCI and CABG in patients with LMS 
disease.
The SYNTAX Trial 
The SYNTAX trial was a multicentre randomised controlled trial of 1,800 
patients with three-vessel or LMS disease comparing CABG with PCI 
using Taxus Express paclitaxel-eluting stents (Boston Scientific).2 A non-
inferiority comparison of the primary endpoint of MACCE was 
undertaken at 1 and 5 years. The 5-year results were published in 2014.7
In the LMS subgroup (n=705) there were no significant differences in 
mortality at 5 years (12.8% PCI versus 14.6% CABG; p=0.53), the 
occurrence of MACCE (36.9% PCI versus 31% CABG; p=0.12) and MI 
(8% PCI versus 5% CABG). However, CABG had a higher stroke rate 
(1.5% PCI versus 4.3% CABG; p=0.05) and PCI had a significantly higher 
rate of repeat revascularisation (26.7% PCI versus 15.5% CABG; 
p<0.001). In patients with high SYNTAX scores, MACCE was significantly 
increased with PCI (high score, 46.5% PCI versus 29.7% CABG; 
p=0.003).8 At 10 years, no significant difference existed in all-cause 
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death between PCI and CABG. However, CABG provided a significant 
survival benefit in patients with three-vessel disease, but not in 
patients with LMS disease.9
The SYNTAX Score and its Role
The SYNTAX score is a method of quantifying the angiographic 
appearance of coronary artery lesions based on their anatomical 
location and complexity to treat by PCI. It is an additive score of all the 
lesions and therefore reflects the quantity of myocardium at risk. It has 
been shown to be predictive of adverse outcomes following PCI but 
less so after CABG, since the success of CABG does not only depend on 
the lesions themselves, but also on nature of the coronary lesions 
among other factors.10
It must be remembered that as a static, non-physiological anatomical 
score it does not take account of patient factors, such as comorbidities, 
cardiac function or patient preference. Although current European 
guidelines recommend the SYNTAX score as an assessment of 
severity of coronary artery disease, they do not recommend its 
routine use to determine PCI versus CABG.11 SYNTAX scoring should 
be interpreted with caution in the context of a balanced 
multidisciplinary team (MDT).
PRECOMBAT
The PRECOMBAT trial was a randomised controlled trial of 600 patients 
with unprotected LMS disease to undergo PCI with a sirolimus-eluting 
stent or CABG. Once again this was a non-inferiority study, with the 
primary endpoint being MACCE.4,5 In PRECOMBAT, mortality at 5 years 
was 5.7% for PCI versus 7.9% for CABG (p=0.32) and MACCE was 17.5% 
for PCI versus 14.3% for CABG (p=0.26). The incidence of MI (2% PCI 
versus 1.7% CABG; p=0.76) and stroke (0.7% PCI versus 0.7% CABG; 
p=0.99) were not significantly different. However, as in the SYNTAX trial, 
the rate of repeat revascularisation was higher in the PCI group (13.0% 
PCI versus 7.3% CABG; p=0.020). 
NOBLE
NOBLE was a prospective, randomised, open-label, non-inferiority trial 
carried out at 36 hospitals in nine northern European countries.12,13 A 
total of 1,201 patients with LMS disease requiring revascularisation 
were enrolled and randomly assigned (1:1) to receive PCI or CABG. 
Of note, NOBLE did not use SYNTAX score as a criterion, but instead 
excluded patients with more than three additional coronary lesions or 
more complex coronary lesions. A total of 598 patients were allocated 
to PCI and 603 to CABG. At 5 years, all-cause mortality and cardiac 
death occurred in 9% and were the same after both procedures with 
MACCE rates of 28% for PCI versus 19% for CABG (p=0.0002). The latter 
exceeded the non-inferiority threshold and CABG was significantly 
better than PCI. Non-procedural MI was higher after PCI (8% PCI versus 
3% CABG; p=0.0002). Patients treated with PCI had higher rates of 
repeat revascularisation (17% PCI versus 10% CABG; p=0.0009).12
EXCEL
The EXCEL trial is a prospective, randomised, open-label, non-inferiority 
trial of 1,905 patients of low or intermediate anatomical complexity. A 
total of 948 patients received fluoropolymer-based-cobalt-chromium 
everolimus-eluting stent and 957 underwent CABG. At 3 years, death, 
stroke, MI or revascularisation occurred in 23.1% of the patients in the 
PCI group and in 19.1% in the CABG group (p=0.01 for noninferiority; 
p=0.10 for superiority).14
In the EXCEL trial at 5 years, the authors reported that a primary 
outcome event had occurred in more patients with PCI, but this was 
not significant (22.0% PCI versus 19.2% CABG; p=0.13).1 However, the 
incidence of all-cause mortality was significantly higher in the PCI 
group (13.0% PCI versus 9.9% CABG, OR 1.38, 95% CI [1.03–1.85]). The 
incidences of cardiovascular death (5.0% PCI versus 4.5% CABG, 0.5 
percentage points, OR 1.13) and MI (10.6% PCI versus 9.1% CABG) were 
not significantly different. All cerebrovascular events were less frequent 
after PCI than after CABG (3.3% PCI versus 5.2% CABG; −1.9 percentage 
points; OR 0.61), although the incidence of stroke was not significantly 
different (2.9% versus 3.7%; −0.8 percentage points; OR 0.78). They 
report that repeat revascularisation was more frequent after PCI than 
after CABG (17.2% versus 10.5%). The authors conclude that there was 
no significant difference between PCI and CABG in respect of the 
composite outcome of death, stroke or MI at 5 years.
EXCEL and NOBLE have shown contradictory results both at 3- and 
5-year follow-up. This is probably related to their inclusion criteria, 
possible crossover of patients in EXCEL from PCI group to CABG 
between 3 and 5 years and several other factors, which are argued 
comprehensively by Park et al.15 A summary of these trials is shown in 
Table 1.
Non-inferiority Trials
Randomised controlled trials are thought to be the gold standard in 
comparing two modalities of treatment compared to registries, which 
may or may not be propensity matched. The main strength of a 
randomised controlled trial is avoiding bias. However, there are several 
weaknesses, including a very small number of potentially eligible 
patients who can be included resulting in only a small number of 
patients being studied, atypical patient populations, short duration of 
follow-up, large number of crossovers and being expensive. In contrast, 
registries can recruit large number of patients, represent real-world 
practice and they are relatively cheap. However, they suffer from bias 
and confounding factors at various levels.
There has been an explosion of non-inferiority trials in cardiovascular 
diseases like the trials described in this paper. Bikdeli et al. report that 
non-inferiority cardiovascular trials are increasingly being published by 
the highest impact journals, with 79% funded by private industries and 
8% funded by non-profit organisations.16 Between 1990 and 2016, 111 
cardiovascular non-inferiority trials were published. Eighty-six of these 
trials, many of which were large multicentre studies, claimed tested 
new interventions were non-inferior to the compared therapy and only 
eight demonstrated inferiority. 
Adverse Media Attention
The publication of the EXCEL trial was followed by serious concerns 
raised about its methodology and the integrity of its results.17–19 The trial 
was the subject of a BBC Newsnight programme in December 2019.20 
The programme raised concerns about the validity of the conclusions 
of the trial, whether important data had been withheld, and raised the 
possibility that the study was inherently flawed from the outset because 
of conflicts of interest amongst the investigators, given that it had been 
financed by stent manufacturers.
As a result of these very serious allegations, the European Association of 
Cardiothoracic Surgery (EACTS) and European Society of Cardiology 
(ESC) guideline group withdrew their support for the joint EACTS/ESC 
statement on the management of patients with LMS disease, until a full 
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independent analysis of the EXCEL trial data had been carried out.18,19 
EACTS summarised its concerns because of the 35% increased risk of 
death in the PCI group, failure of the authors to publish the data using the 
Universal Definition of MI, emerging mortality data that was available to 
the data safety monitoring board not being made available to the 
guideline task force and alleged conflict of interest. Later, in a letter to 
EXCEL primary investigators, Domenico Pagano on behalf of EACTS 
invited the authors to make the raw data available to the Clinical Trials 
Unit at University College London for re-analysis.19
The British Cardiovascular Intervention Society (BCIS) also released a 
statement on 11 December 2019 reassuring the patients undergoing 
stent procedures and that patients with LMS disease will be discussed 
by a multidisciplinary heart team and the outcome of this discussion 
will be shared with patients in order to reach a final decision.21
The president of the Society for Cardiothoracic Surgery (SCTS), Mr 
Richard Page, wrote on 18 December 2019: “A number of colleagues 
are understandably concerned that the joint statement [by SCTS, British 
Cardiovascular Intervention Society and British Cardiovascular Society] 
did not clarify the current situation/evidence for the treatment of Left 
Main Stem stenosis, given that doubts have been raised about the 
integrity of Excel.22,23 There was uncertainty within the cardiac surgical 
community as to the position taken by the SCTS. Clearly an explanation 
is required, which is why I am writing to you again. Very soon after the 
Newsnight programme we were made aware of patients and relatives 
who were concerned as to whether they were receiving the right 
treatment, even to the extent that some were questioning if stents 
were safe in any situation. Therefore there was a real and pressing 
need to be able to reassure patients and their families that they could 
trust cardiovascular physicians and surgeons in the UK to give balanced 
and appropriate advice, and that each and every patient will have 
access to specific and individualised treatment, notwithstanding the 
questions raised regarding the validity of the Excel trial. We did not feel 
that a statement from SCTS alone would be constructive to the situation 
and it would be more sensible and reassuring to patients, relatives and 
the NHS to see collaboration and a joint statement from the professional 
societies that are responsible for all aspects of decision making in this 
pattern of coronary disease.”
A further letter to SCTS members from the President on 17 February 
2020 provided an update on the situation: “The SCTS agrees with EACTS 
(and indeed all other cardiothoracic surgical societies throughout the 
world who have expressed an opinion) that on current evidence 
coronary bypass surgery is superior to stenting in the treatment of the 
vast majority of patients with LMSS and remains the best treatment 
that we can offer. Nevertheless when the risks of surgery are significant, 
stenting for LMSS may be a safer alternative in some circumstances.” 
Many of our patients understandably find the adverse media attention 
and various statements confusing and worrying. We discuss this in 
more detail in the Patient’s Choice section. Unpublished data of a 
survey of the understanding of patients of the extent and nature of 
their coronary artery disease shows that almost no patient can tell the 
difference between LMS disease, triple vessel disease and/or significant 
coronary artery disease. 
Controversies of the EXCEL Trial
There are several controversies of the methodology and conduct of the 
EXCEL trial that have been addressed, including the following:16,24 
• The EXCEL investigators use the Society for Cardiovascular 
Angiography and Interventions (SCAI) definition of peri-procedural 
MI rather than the Universal Definition of MI.25,26 The use of SCAI 
caused the reporting of 37% higher occurrence of MI in the CABG 
group. Furthermore, the use of Universal Definition of MI would have 
allowed a fairer comparison of EXCEL with other trials. In addition, 
Ruel et al. showed that the SCAI definition of MI exaggerated 
procedural MI after CABG.27 
• The incidence of all-cause mortality was significantly higher in the 
PCI group (13.0% PCI versus 9.9% CABG; OR 1.38; 95% CI [1.03–
1.85]). There is an increasing divergence during the follow-up period 
for death in favour of CABG. At 5 years, the mortality rate was 
significantly higher in the PCI group compared to CABG. The EXCEL 
investigators had classified all-cause mortality as a secondary 
endpoint and reported that its statistical significance was uncertain. 
The majority of the trials have all-cause mortality as a primary 
endpoint and therefore hiding of all-cause mortality is disingenuous. 
• Repeat revascularisation, which has been shown to be an independent 
predictor of death, MI and stroke, was significantly higher in the PCI 
group.28 Repeat revascularisation as an outcome measure has 
significant implications for patient’s quality of life and health service 
economy and has been used as a primary outcome measure in 
earlier trials.29,5 We believe that repeat revascularisation should have 
Table 1: The 5-year Outcomes of Randomised Trials Comparing PCI with CABG in the Treatment of Left Main Stem
SYNTAX2 PRECOMBAT5 NOBLE12 EXCEL1
Publication year 2014 2015 2020 2019
Number of patients 705 600 1,201 1,905
Length of follow-up 5 years 5 years 5 years 5 years
MACCE MACCE MACCE Composite death, stroke or MI
Primary Outcome (PCI versus CABG)
36.9 versus 31% (p=0.12) 17.5 versus 14.3% (p=0.26) 28 versus 19% (p=0.0002) 22 versus 19.2% (p=0.13)
Secondary Outcomes (PCI versus CABG)
All-cause mortality 12.8 versus 14.6% (p=0.53) 5.7 versus 7.9% (p=0.32) 9 versus 9% (p=0.68) 13 versus 9.9%
MI 8.2 versus 4.8% (p=0.1) 2 versus 1.7% (p=0.76) 8 versus 3% (p=0.0002) 10.6 versus 9.1%
Stroke 1.5 versus 4.3% (p=0.03) 0.7 versus 0.7% (p=0.99) 4 versus 2% (p=0.11) 2.9 versus 3.7%
Repeat revascularisation 26.7 versus 15.5% (p<0.001) 13 versus 7.3% (p=0.020) 17 versus 10% (p=0.0009) 17.2 versus 10.5%
CABG = coronary artery bypass graft; MACCE = major cardiac or cardiovascular events; PCI = percutaneous coronary intervention.
EUROPEAN CARDIOLOGY REVIEW
Special Focus on the EXCEL Trial
been considered as primary endpoint. Furthermore, repeat 
revascularisation during follow-up was performed less frequently 
after CABG than PCI and was associated with increased mortality 
after both procedures.30 
• The HR of the composite of death, stroke and MI shifted from being 
in favour of PCI at 30 days to CABG during the follow-up period. This 
indicates that CABG is the preferred option in patients with longer 
life expectancy. 
• Unlike the PCI group, the CABG group was heterogeneous in both 
using off-pump technique and arterial grafting. Overall 29.4% of the 
CABG operations were off-pump. In a subgroup analysis, Benedetto 
et al. reported a significantly higher all-cause mortality in the off-
pump compared to on-pump patients at 3 years (8.8% off-pump 
versus 4.5% on-pump).31 
Furthermore, there is strong evidence in patients undergoing CABG for 
the use of multiple arterial grafting improving survival.32–35 However, 
only 24% of patients in EXCEL received bilateral mammary arteries and 
6% received radial arteries. In such a heterogeneous population, it is 
difficult to assess the impact of the known benefits of arterial 
revascularisation.36 These factors should be taken into account when 
analysing the EXCEL data. 
Assessment of Left Main Stem
Coronary angiography has traditionally been the gold-standard for 
diagnosis of coronary artery disease and uses anatomical evaluation of 
the coronary arteries through multiple angiographic views and thereby 
identify stenoses that necessitate further intervention.37 Studies have 
demonstrated a poor correlation between angiographic appearance of 
a coronary artery to the true degree of stenosis in some cases which 
can be observer dependent.38 
Fractional flow reserve (FFR) has been increasingly used along with 
angiography in PCI. FFR is measured during coronary catheterisation by 
passing a pressure-monitoring guide wire distal to the coronary lesion 
and inducing maximal hyperaemia, usually through intravenous or 
intracoronary adenosine administration to cause vasodilation.39 It 
measures the drop in perfusion pressure across a stenosis, therefore 
representing its physiological effect on myocardial blood flow. Its use is 
widespread in PCI, though its role in CABG remains uncertain. We carried 
out a systematic review and meta-analysis to evaluate current evidence 
on outcomes following FFR-guided CABG compared to angiography-
guided CABG.40 We showed that there was no reduction in repeat 
revascularisation or postoperative MI with FFR. In addition, FFR-guided 
CABG provided a reduction in mortality, but this was not reported to be 
due to cardiac causes. There may be a role for FFR in CABG, but large-
scale randomised trials are required to establish its value.
The Role of the Multidisciplinary Team Meeting 
“The mind is an attribute of the individual. There is no such thing as a 
collective brain. The primary act – the process of reason – must be 
performed by each man alone. We can divide a meal among many men. 
We cannot digest it in a collective stomach. No man can use his lungs 
to breathe for another man. No man can use his brain to think for 
another.”
The Fountainhead, Ayn Rand, 1943
The Heart Team is an integral part of the patient care pathway for those 
with complex coronary artery disease. In 2014, the first joint ESC/EACTS 
guidelines on myocardial revascularisation were published to help 
inform Heart Teams of current best evidence on the topic.41 In 2013, 
Head et al. reported that the concept of the Heart Team was not widely 
implemented. Decision-making was shown to remain suboptimal, there 
was large variability in PCI to CABG ratios, which could have been 
predominantly the consequence of physician-related factors, raising 
concerns regarding overuse, underuse and inappropriate selection of 
revascularisation.42
Our group showed that despite the introduction of joint cardiology and 
surgical international guidelines, a significant number of patients were 
receiving inappropriate PCI against those guidelines.43 
Subsequent guidelines in 2018 specifically recommend the use of Heart 
Team for decision making in patients with coronary artery disease.10 They 
give a Class 1C recommendation (meaning it is recommended or indicated 
based on expert opinion) for interdisciplinary protocols for common case 
scenarios to implement the appropriate revascularisation strategy in 
accordance with current guidelines. Furthermore, they state individual 
discussion should occur for all complex cases and that the Heart Team 
should provide a balanced multidisciplinary decision-making process.
This decision-making process is guided by the combined personal 
experience of the Heart Team in conjunction with current best 
evidence. Evidence obtained from large randomised controlled trials 
will often be relied upon by the Heart Team. Therefore, it is imperative 
that such studies have been conducted with integrity and the results 
reported accurately.
Assessing the effectiveness and reproducibility of a coronary Heart 
Teams decisions is difficult. A study from the UK has previously shown 
that 93% of decisions on 399 patients are implemented and when re-
discussed at a later date 80% of decisions are unchanged.44 This of 
course does not account for patients who are treated without the 
benefit of Heart Team discussion.
In day-to-day practice, clinicians are unable to discuss the nuanced 
findings of these trials for each patient. Therefore, the role of Heart 
Team and MDT have been emphasised.45,42
In the UK, CABG comprises approximately 40% of the adult cardiac 
surgery operations per annum. A total of 14,527 isolated non-
emergency CABG operations were performed between April 2017 and 
March 2018.46 However, data are not available as to what proportion 
had LMS disease. Similarly, there is a significant number of PCIs 
performed for multivessel disease, but it is difficult to extract from the 
BCIS database what percentage had LMS disease. The question is 
whether every single patient with LMS can be discussed in an MDT 
with Heart Team setting.
The authors of this article suspect that only a small proportion of LMS 
patients are discussed at MDTs. The treatment decision is clinician-
dependent and is often related to the culture of a unit. Unfortunately, 
the decision around management of LMS patients can often become 
dominated by a discussion around technical feasibility of PCI. This 
conflation of two separate issues may not always be in the wider 
interest for patients with this disease. 
The Patient’s Choice 
It is difficult for clinicians – let alone patients – to navigate their way 
around these complex trials with their inherently nuanced conclusions. 
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Patients need accurate information in order to make an informed 
decision. The quality of any discussion can influence which decision is 
reached. Many patients exhibit a high degree of suggestibility, 
meaning that it is possible to influence their decision-making in a 
particular direction, depending on how or even the order in which 
information is relayed. An example of this is if a patient is asked if they 
would like a procedure that will help them. The proposed procedure is 
not surgery, but similar to an angiogram, and they could go home 
soon after. This is then contrasted with major cardiac surgery, 
describing a midline chest incision, deliberately stopping the heart, 
multiple limb incisions and a 1-week hospital stay plus a total recovery 
time of 3 months. 
What may be perceived by cardiologists as a prohibitive risk for surgery, 
then becomes conflated with patient choice. Four pillars of medical 
ethics ensure that, when considered together, everyone receives the 
same standard of healthcare. The same principles also serve to provide 
guidance to doctors in approaching the care of their patients. These 
four pillars are autonomy, beneficence, non-maleficence and justice. 
The founding ethical principle that is mainly undermined in the above 
scenarios is patient autonomy. That is, the universal right of competent 
adults to make informed decisions about their own medical care. Thus, 
by failing to appraise patients properly of the risks and benefits of all 
treatments, including no treatment, patient choice is suddenly 
transformed, to something more akin to dealer’s choice. For the 
uninitiated, the latter phrase also describes a particular style of poker, 
where each player may deal a different variant.
Informed Decision-making 
In view of some of the controversies highlighted by the EXCEL trial 
data and its natural extrapolation to the management of coronary 
artery disease in general, there is perhaps now an opportunity to 
improve the role of the MDT/Heart Team. A more systematic approach 
would be to openly discuss all patients with LMS who require elective 
coronary intervention, with a structured proforma completed in each 
case. Essential information should include presence of important risk 
factors such as diabetes, defining the vessels to be grafted, potential 
benefits of complete versus incomplete revascularisation, therefore 
possibility and extent of arterial grafting and consultation by both the 
cardiologist and the cardiac surgeon. The Heart Team meeting should 
have an agreed attendance of cardiologists, surgeons and others to 
achieve quoracy. It would also benefit from a neutral chair. The final 
decision as to the mode of treatment should be based on real-world 
evidence and not “let’s wait for the next generation of stents and use 
of multiple and stronger anti-platelet medications”. Facts emerging 
from the most recent trials have not, by and large, been catalysed by 
newer stent technology. 
Conclusion
We have attempted to set out the context of the recent events that 
have led to confusion. The SYNTAX trial was the first randomised trial to 
compare CABG and PCI in patients with complex coronary disease. The 
definitive results confirmed that CABG should remain the standard of 
care for patients with complex coronary lesions. For patients with less 
complex lesions, or LMS disease, SYNTAX found that PCI is an 
acceptable alternative, even though it was not designed to assess the 
overall efficacy of PCI versus CABG. It was against this background, that 
the EXCEL trial was designed to investigate the newer-generation DES 
versus CABG in patients with low-risk or intermediate-risk LMS disease. 
The initial conclusion of the EXCEL authors, that there was no significant 
difference between PCI and CABG in respect of the composite 
endpoints of death, stroke or MI at 5 years, has subsequently been 
called into question. This is related to controversies regarding the trial 
methodology, disagreements about which definition of peri-procedural 
MI was used and alleged investigator conflicts of interest. The EXCEL 
debacle has, to some extent, undermined public confidence in medical 
research in general and in clinical trials in particular. 
It is unlikely that there will be a further large randomised trial aimed at 
addressing the issue of the optimum method of revascularisation for 
LMS disease but further subgroup analyses from these trials may be 
hypothesis generating.
There are already good quality data that suggest CABG confers a 
survival advantage for patients with LMS disease. Most authors 
recommend genuine discussions take place between cardiologists and 
cardiac surgeons regarding optimal treatment for complex coronary 
artery disease or LMS disease. This does not always happen in the way 
that it should. In some cases the invasiveness of CABG is emphasised 
to engineer patient choice in favour of PCI. 
We advocate a systematic approach to the Heart Team Meeting, with 
a structured proforma, agreed quorum and a neutral chair. We must 
apply judicious management to coronary artery disease. Who should 
lead this clarion call? We invite key opinion leaders of cardiac surgery 
and cardiology, namely their respective professional organisations, to 
rise to the challenge of ensuring the treatment of particularly LMS 
patients is based on sound ethical and scientific principles. We owe 
this much to our patients; nothing less will suffice and they are the 
ultimate beneficiaries. 
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